Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance
Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance
复制标题
DOI：
10.1007/s10549-008-0239-3
复制
发表时间：
2009-10-01
影响因子：
3.8
通讯作者：
Mavroudis, Dimitris
中科院分区：
文献类型：
--
作者：
Apostolaki, Stella;Perraki, Maria;Mavroudis, Dimitris
评估 HER2 mRNA 是否可以用作可手术乳腺癌女性循环肿瘤细胞 (CTC) 的标记物。开发了一种巢式 RT-PCR 检测方法，用于检测 HER2 mRNA 阳性 CTC。对 216 名早期乳腺癌女性在辅助治疗前采集的血液进行 HER2 mRNA 阳性细胞检测，以评估其预后价值。 HER2 mRNA 的巢式 RT-PCR 显示出高灵敏度，而在健康供体的血液中无法识别出 HER2 mRNA 阳性细胞。 216 名患者中有 53 名 (24.5%) 检测到 HER2 mRNA 阳性 CTC，HER2 mRNA 检测与无病生存期 (DFS; P < 0.0001) 和总生存期 (OS; P = 0.004) 降低相关。在多变量分析中，HER2 mRNA 阳性 CTC 的检测成为 DFS (P = 0.0001) 和 OS (P = 0.003) 的独立预后因素。 HER2 mRNA 可能是检测早期乳腺癌患者 CTC 的有价值的预后标志物。
To evaluate whether HER2 mRNA could be used as a marker of circulating tumor cells (CTCs) in women with operable breast cancer. A nested RT-PCR assay was developed and used for the detection of HER2 mRNA-positive CTCs. Blood from 216 women with early breast cancer obtained before adjuvant treatment was tested for HER2 mRNA-positive cells to assess their prognostic value. Nested RT-PCR for HER2 mRNA showed high sensitivity whereas no HER2 mRNA-positive cells could be identified in the blood of healthy donors. HER2 mRNA-positive CTCs were detected in 53 (24.5%) of 216 patients and HER2 mRNA detection was associated with reduced disease-free survival (DFS; P < 0.0001) and overall survival (OS; P = 0.004). In multivariate analysis, detection of HER2 mRNA-positive CTCs emerged as independent prognostic factor for DFS (P = 0.0001) and OS (P = 0.003). HER2 mRNA could be a valuable prognostic marker for the detection of CTCs in early breast cancer patients.